Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
Oxford BioMedica plc announced that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company’s proprietary 5T4 tumour antigen. Following proof-of-concept, the agreement includes an option for ImaginAb to negotiate an exclusive license for commercialisation of an in vivo 5T4-based imaging diagnostic. On that basis, Oxford BioMedica could receive proceeds of up to US$4 million in initiation and development milestone payments, in addition to royalties on product sales, subject to the achievement of certain programme objectives.
ImaginAb plans to develop an in vivo diagnostic imaging agent for positron emission tomography (PET), a nuclear medicine imaging technique that produces a three-dimensional image of functional processes in the body, which will initially be applied to ovarian cancer imaging.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Thermo Fisher Scientific Strengthens Presence in India with Acquisition of Chemito Technologies
Bioelectronics: Invention of the pH imaging microscope for applications including treatment of Alzheimer’s disease.
New technique shows in detail where drug molecules hit their targets in the body - The new method could speed the development of many new drugs
Thermo Fisher Scientific and George Mason University Partner in Protein Biomarker Research Project - Collaboration Aims to Accelerate Verification and Validation of Protein Biomarkers for Earlier Disease Diagnosis and Therapeutic Efficacy
Flemish researchers provide the first experimental evidence of dynamic allostery in protein regulation
Revolutionary images of the birth of crystals - A team from the UNIGE has succeeded in visualizing crystal nucleation - the stage that precedes crystallization - that was invisible until now